×

In vivo temporal control of activatable matrix-degrading enzymes

  • US 20100003237A1
  • Filed: 03/06/2009
  • Published: 01/07/2010
  • Est. Priority Date: 03/06/2008
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating a disease or condition of the extracellular matrix (ECM), comprising sub-epidermally administering to the ECM an activatable matrix-degrading enzyme (AMDE) and an activator, wherein:

  • the AMDE is inactive in the ECM in the absence of the activator;

    the activator, when administered to the ECM, provides an activating condition for the enzyme such that the AMDE is active; and

    the activating condition is not present in the ECM prior to administration of the activator.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×